Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase

Potential of Protein Phosphatase Inhibitor 1 As Biomarker of Pancreatic β-Cell Injury In Vitro and In Vivo

(2013) Lei Jiang et al.   DIABETES

Prediction of Type 1 Diabetes

(2013) H. A. Erlich et al.   DIABETES

In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions

(2013) E. Mbunwe et al.   DIABETOLOGIA

The use of intermediate endpoints in the design of type 1 diabetes prevention trials

(2013) Jeffrey P. Krischer et al.   DIABETOLOGIA

The diagnosis of insulitis in human type 1 diabetes

(2013) M. L. Campbell-Thompson et al.   DIABETOLOGIA

Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children

(2013) P. Achenbach et al.   DIABETOLOGIA

Circulating miR-375 as a Biomarker of β-Cell Death and Diabetes in Mice

(2013) Suheda Erener et al.   ENDOCRINOLOGY

Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children

(2013) Anette G. Ziegler et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients

(2012) F. K. Gorus et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

HLA-A*24 Is an Independent Predictor of 5-Year Progression to Diabetes in Autoantibody-Positive First-Degree Relatives of Type 1 Diabetic Patients

(2012) E. Mbunwe et al.   DIABETES

Through the Fog: Recent Clinical Trials to Preserve  -Cell Function in Type 1 Diabetes

(2012) C. J. Greenbaum et al.   DIABETES

Effect of the PTPN22 and INS Risk Genotypes on the Progression to Clinical Type 1 Diabetes After the Initiation of  -Cell Autoimmunity

(2012) J. Lempainen et al.   DIABETES

The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial-Type 1

(2012) J. M. Sosenko et al.   DIABETES

Effects of Non-HLA Gene Polymorphisms on Development of Islet Autoimmunity and Type 1 Diabetes in a Population With High-Risk HLA-DR,DQ Genotypes

(2012) A. K. Steck et al.   DIABETES

Diagnosis and Classification of Diabetes Mellitus

(2012)   DIABETES CARE

Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population: Receiver operating characteristic analysis

(2012) P. Xu et al.   DIABETES CARE

Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes

(2012) Martha Campbell-Thompson et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Primary and secondary prevention of Type 1 diabetes

(2012) J. S. Skyler   DIABETIC MEDICINE

A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes

(2012) C Winkler et al.   GENES AND IMMUNITY

Glucose and Inflammation Control Islet Vascular Density and β-Cell Function in NOD Mice

(2011) Eitan M. Akirav et al.   DIABETES

Single Insulin-Specific CD8+ T Cells Show Characteristic Gene Expression Profiles in Human Type 1 Diabetes

(2011) S. Luce et al.   DIABETES

Evidence That Nasal Insulin Induces Immune Tolerance to Insulin in Adults With Autoimmune Diabetes

(2011) S. Fourlanos et al.   DIABETES

Long-Term Outcome of Individuals Treated With Oral Insulin: Diabetes Prevention Trial-Type 1 (DPT-1) oral insulin trial

(2011) K. Vehik et al.   DIABETES CARE

Reduced Prevalence of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Young Children Participating in Longitudinal Follow-Up

(2011) H. Elding Larsson et al.   DIABETES CARE

An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age

(2011) I. Vermeulen et al.   DIABETOLOGIA

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies

(2011) Tom L. Van Belle et al.   PHYSIOLOGICAL REVIEWS

A historical view from thirty eventful years of immunotherapy in autoimmune diabetes

(2011) Jean-François Bach et al.   SEMINARS IN IMMUNOLOGY

Insulitis in human type 1 diabetes

(2011) Peter In't Veld   Islets

Effect of HLA Class I and Class II Alleles on Progression From Autoantibody Positivity to Overt Type 1 Diabetes in Children With Risk-Associated Class II Genotypes

(2010) K. Lipponen et al.   DIABETES

Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man

(2010) J. S. Skyler et al.   DIABETES

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

(2010) B. Keymeulen et al.   DIABETOLOGIA

Etiology of Type 1 Diabetes

(2010) John A. Todd   IMMUNITY

Prediction and Pathogenesis in Type 1 Diabetes

(2010) Anette-G. Ziegler et al.   IMMUNITY

Dietary Intervention in Infancy and Later Signs of Beta-Cell Autoimmunity

(2010) Mikael Knip et al.   NEW ENGLAND JOURNAL OF MEDICINE

Type 1 Diabetes TrialNet-An International Collaborative Clinical Trials Network

(2009) Jay S. Skyler et al.   Annals of the New York Academy of Sciences

Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic Patients

(2009) R. Hilbrands et al.   DIABETES

Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients

(2009) E. Vandemeulebroucke et al.   DIABETES & METABOLISM

Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials

(2009) J. De Grijse et al.   DIABETOLOGIA

Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients

(2009) E. Vandemeulebroucke et al.   DIABETOLOGIA

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Simultaneous Measurement of Plasma Concentrations of Proinsulin and C-Peptide and Their Ratio with a Trefoil-Type Time-Resolved Fluorescence Immunoassay

(2008) P. E.M. De Pauw et al.   CLINICAL CHEMISTRY

Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of  -Cell Function in Therapeutic Trials in Type 1 Diabetes

(2008) C. J. Greenbaum et al.   DIABETES CARE

Restoring a functional β-cell mass in diabetes

(2008) D. Pipeleers et al.   DIABETES OBESITY & METABOLISM

Extreme genetic risk for type 1A diabetes in the post-genome era

(2008) Erin E. Baschal et al.   JOURNAL OF AUTOIMMUNITY

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial

(2008) Kirsti Näntö-Salonen et al.   LANCET

GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes

(2008) Johnny Ludvigsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cellular Islet Autoimmunity Associates with Clinical Outcome of Islet Cell Transplantation

(2008) Volkert A. L. Huurman et al.   PLoS One